journal article·2025-07-16Open access

Engineering Lymphatic Transport of Nanoparticles through Emulsion Polymerization

Alexander J. Heiler, Tae Hee Yoon, Maya Levitan, Yunus Alapan, Susan N. Thomas

ACS Applied Materials & Interfaces· Volume 17· Issue 28

Abstract

High Resolution Image Download MS PowerPoint Slide A library of lymphatic-targeting poly(propylene sulfide) nanoparticles (NPs) synthesized with copolymers of different properties at various concentrations was created. The effects of copolymer type and concentration on NP properties were explored, along with the transport behaviors of the NP formulations using in vitro assays that modeled diffusion through the skin interstitium and permeability across and uptake into lymphatic endothelial cells that predicted their in vivo lymphatic transport and uptake. By tuning the properties of the copolymer surfactants used during NP synthesis, both the NP characteristics and transport properties could be controlled, enabling the design of lymphatic-targeting drug delivery vehicles and imaging agents with varying behaviors.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Lymphatic System and Diseases · Advancements in Transdermal Drug Delivery · Noise Effects and Management

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Parker H. Petit Institute for Bioengineering and Bioscience

Georgia Institute of Technology

School of Chemical and Biomolecular Engineering

George W. Woodruff School of Mechanical Engineering

Wallace H. Coulter Department of Biomedical Engineering

Georgia Institute of Technology and Emory University

Winship Cancer Institute

Emory University

Funding

Fulbright Association · National Science Foundation Graduate Research Fellowship Program · National Cancer Institute · Shurl and Kay Curci Foundation

References (48)

Show source-provided references
1. 10.1016/j.coche.2014.11.00310.1016/j.coche.2014.11.003 ↗
2. 10.1038/s41578-019-0110-710.1038/s41578-019-0110-7 ↗
3. 10.1111/imr.1239910.1111/imr.12399 ↗
4. 10.1016/j.semcdb.2014.11.01210.1016/j.semcdb.2014.11.012 ↗
5. 10.1158/2326-6066.CIR-14-0019-T10.1158/2326-6066.CIR-14-0019-T ↗
6. 10.1016/j.biomaterials.2013.10.00310.1016/j.biomaterials.2013.10.003 ↗
7. 10.1016/j.jconrel.2023.10.00210.1016/j.jconrel.2023.10.002 ↗
8. 10.4110/in.2022.22.e910.4110/in.2022.22.e9 ↗
9. 10.1172/JCI12092310.1172/JCI120923 ↗
10. 10.2458/lymph.463810.2458/lymph.4638 ↗
11. 10.1007/BF0298724410.1007/BF02987244 ↗
12. 10.1016/S0748-7983(97)92885-710.1016/S0748-7983(97)92885-7 ↗
13. 10.3390/pharmaceutics1412275210.3390/pharmaceutics14122752 ↗
14. 10.1016/j.addr.2020.10.00410.1016/j.addr.2020.10.004 ↗
15. 10.1016/j.smim.2021.10153410.1016/j.smim.2021.101534 ↗
16. 10.1021/acs.accounts.0c0026010.1021/acs.accounts.0c00260 ↗
17. 10.1101/2022.06.02.4945510.1101/2022.06.02.49455 ↗
18. 10.1016/j.actbio.2022.03.05410.1016/j.actbio.2022.03.054 ↗
19. 10.1023/A:101211753144810.1023/A:1012117531448 ↗
20. 10.1126/sciadv.abd713410.1126/sciadv.abd7134 ↗
21. 10.1039/D4BM00910J10.1039/D4BM00910J ↗
22. 10.1021/la047804310.1021/la0478043 ↗
23. 10.1007/s00396-017-4141-610.1007/s00396-017-4141-6 ↗
24. 10.1021/acs.macromol.2c0180110.1021/acs.macromol.2c01801 ↗
25. 10.1021/la00024a01610.1021/la00024a016 ↗
26. 10.1007/s13404-011-0015-810.1007/s13404-011-0015-8 ↗
27. 10.1002/adma.20070197510.1002/adma.200701975 ↗
28. 10.1073/pnas.101838210810.1073/pnas.1018382108 ↗
29. 10.1002/anie.20080352610.1002/anie.200803526 ↗
30. 10.1007/s12195-022-00727-x10.1007/s12195-022-00727-x ↗
31. 10.1002/adhm.20230010510.1002/adhm.202300105 ↗
32. 10.1016/j.ijpharm.2023.12368810.1016/j.ijpharm.2023.123688 ↗
33. 10.1016/j.jconrel.2020.09.04210.1016/j.jconrel.2020.09.042 ↗
34. 10.1021/acs.biomac.0c0076910.1021/acs.biomac.0c00769 ↗
35. 10.1038/s41467-022-29121-x10.1038/s41467-022-29121-x ↗
36. 10.1016/j.jcis.2005.12.00910.1016/j.jcis.2005.12.009 ↗
37. 10.1021/bc900444310.1021/bc9004443 ↗
38. 10.1063/1.499992510.1063/1.4999925 ↗
39. 10.1101/2021.03.07.43429810.1101/2021.03.07.434298 ↗
40. 10.1126/sciadv.abq043510.1126/sciadv.abq0435 ↗
41. 10.3390/pharmaceutics1112067110.3390/pharmaceutics11120671 ↗
42. 10.2741/E10210.2741/E102 ↗
43. 10.1002/marc.20030004810.1002/marc.200300048 ↗
44. 10.1038/s41565-020-0679-410.1038/s41565-020-0679-4 ↗
45. 10.1007/s10856-012-4571-010.1007/s10856-012-4571-0 ↗
46. 10.1021/acs.nanolett.0c0375610.1021/acs.nanolett.0c03756 ↗
47. 10.1007/s10856-009-3746-910.1007/s10856-009-3746-9 ↗
48. 10.1146/annurev.immunol.20.100301.06482810.1146/annurev.immunol.20.100301.064828 ↗